GlassScriptPhysician profile
Scott A Nesbitt
NPI 1962419861
$8,526.89
in general payments reported to CMS, 2019-2025
42 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $1,029 · 2021: $1,320 · 2022: $1,089 · 2023: $1,429 · 2024: $1,342 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,166 · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,166.48 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,023.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $893.77 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $856.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $736.45 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $607.18 | 2019-2025 | |
| Amgen INC. | $523.57 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $383.89 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $336.05 | 2019-2025 | Belsomra, Gardasil 9, Verquvo |
| Amarin Pharma, INC. | $333.63 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.04 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $285.39 | 2019-2022 | |
| Exact Sciences Corporation | $236.17 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $214.83 | 2022-2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $187.31 | 2020-2025 | Seglentis, Zoryve, Livalo |
| Allergan, INC. | $160.81 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Nesbitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.